Nell Meosky Luo
CEO, Folia Health
Bio: Nell Meosky Luo is the Founder & CEO of Folia Health, a patient-driven health company where she has led a team to develop a novel method for enabling the collection and use of home-reported outcomes for precision care & research. She was the recipient of the Massachusetts Women in Digital Health award in 2018, and was named to the governor’s Digital Health Council Working Group & Independent Steering Committee in 2019. Nell was also a member of the Mass General – Brigham COVID-19 Task Force. Prior to Folia, Nell was a management consultant at Oliver Wyman, where she focused on strategic transformation across healthcare, consumer goods, and intellectual property sectors, among others. Nell earned her Bachelor’s degree from Yale in History of Science & Medicine and Public Health, graduating cum laude and with Distinction in the major.
Org Info: We’re the first platform to make it possible for individuals to receive truly evidence-based, precise care while contributing to groundbreaking research – all in one place.
What motivated you to pursue your current work?
My brother has a rare immunological disease, and I grew up somewhat flabbergasted by how hard it was to be precise about his care.
What distinct value does your work bring to the digital health field?
We’re building the bedrock of a truly data-driven healthcare system: home-reported outcomes, or HROs. This patient-captured datatype enables better, more granular, patient-level information on how each individual experiences their condition over time, and how they respond to therapies.
How does your work impact your target end-users or stakeholders?
Our dream is that in 2030, individuals will hold a single source of truth, including their own observations, to drive their medical care; clinicians will consider home-reported outcomes an indispensable part of care; and researchers will have quick & easy access to home-tracked insights and willing participants, over a longitudinal period.
What is one exciting update or near-term opportunity that you would like to share with the digital health community?
We’re going to be announcing a new program investigating the full scope of the burden of disease in a poorly-understood condition in the next little bit!
Bio: Nell Meosky Luo is the Founder & CEO of Folia Health, a patient-driven health company where she has led a team to develop a novel method for enabling the collection and use of home-reported outcomes for precision care & research. She was the recipient of the Massachusetts Women in Digital Health award in 2018, and was named to the governor’s Digital Health Council Working Group & Independent Steering Committee in 2019. Nell was also a member of the Mass General – Brigham COVID-19 Task Force. Prior to Folia, Nell was a management consultant at Oliver Wyman, where she focused on strategic transformation across healthcare, consumer goods, and intellectual property sectors, among others. Nell earned her Bachelor’s degree from Yale in History of Science & Medicine and Public Health, graduating cum laude and with Distinction in the major.
Org Info: We’re the first platform to make it possible for individuals to receive truly evidence-based, precise care while contributing to groundbreaking research – all in one place.
What motivated you to pursue your current work?
My brother has a rare immunological disease, and I grew up somewhat flabbergasted by how hard it was to be precise about his care.
What distinct value does your work bring to the digital health field?
We’re building the bedrock of a truly data-driven healthcare system: home-reported outcomes, or HROs. This patient-captured datatype enables better, more granular, patient-level information on how each individual experiences their condition over time, and how they respond to therapies.
How does your work impact your target end-users or stakeholders?
Our dream is that in 2030, individuals will hold a single source of truth, including their own observations, to drive their medical care; clinicians will consider home-reported outcomes an indispensable part of care; and researchers will have quick & easy access to home-tracked insights and willing participants, over a longitudinal period.
What is one exciting update or near-term opportunity that you would like to share with the digital health community?
We’re going to be announcing a new program investigating the full scope of the burden of disease in a poorly-understood condition in the next little bit!